Planning influenza vaccination programs: a cost benefit model

<p>Abstract</p> <p>Background</p> <p>Although annual influenza vaccination could decrease the significant economic and humanistic burden of influenza in the United States, immunization rates are below recommended levels, and concerns remain whether immunization programs...

Full description

Bibliographic Details
Main Authors: Duncan Ian G, Taitel Michael S, Zhang Junjie, Kirkham Heather S
Format: Article
Language:English
Published: BMC 2012-07-01
Series:Cost Effectiveness and Resource Allocation
Subjects:
Online Access:http://www.resource-allocation.com/content/10/1/10
_version_ 1817994224596942848
author Duncan Ian G
Taitel Michael S
Zhang Junjie
Kirkham Heather S
author_facet Duncan Ian G
Taitel Michael S
Zhang Junjie
Kirkham Heather S
author_sort Duncan Ian G
collection DOAJ
description <p>Abstract</p> <p>Background</p> <p>Although annual influenza vaccination could decrease the significant economic and humanistic burden of influenza in the United States, immunization rates are below recommended levels, and concerns remain whether immunization programs can be cost beneficial. The research objective was to compare cost benefit of various immunization strategies from employer, employee, and societal perspectives.</p> <p>Methods</p> <p>An actuarial model was developed based on the published literature to estimate the costs and benefits of influenza immunization programs. Useful features of the model included customization by population age and risk-level, potential pandemic risk, and projection year. Various immunization strategies were modelled for an average U.S. population of 15,000 persons vaccinated in pharmacies or doctor’s office during the 2011/12 season. The primary outcome measure reported net cost savings per vaccinated (PV) from the perspective of various stakeholders.</p> <p>Results</p> <p>Given a typical U.S. population, an influenza immunization program will be cost beneficial for employers when more than 37% of individuals receive vaccine in non-traditional settings such as pharmacies. The baseline scenario, where 50% of persons would be vaccinated in non-traditional settings, estimated net savings of $6 PV. Programs that limited to pharmacy setting ($31 PV) or targeted persons with high-risk comorbidities ($83 PV) or seniors ($107 PV) were found to increase cost benefit. Sensitivity analysis confirmed the scenario-based findings.</p> <p>Conclusions</p> <p>Both universal and targeted vaccination programs can be cost beneficial. Proper planning with cost models can help employers and policy makers develop strategies to improve the impact of immunization programs.</p>
first_indexed 2024-04-14T01:49:11Z
format Article
id doaj.art-ebf8dc9bf69d4264b8e49889841f535b
institution Directory Open Access Journal
issn 1478-7547
language English
last_indexed 2024-04-14T01:49:11Z
publishDate 2012-07-01
publisher BMC
record_format Article
series Cost Effectiveness and Resource Allocation
spelling doaj.art-ebf8dc9bf69d4264b8e49889841f535b2022-12-22T02:19:24ZengBMCCost Effectiveness and Resource Allocation1478-75472012-07-011011010.1186/1478-7547-10-10Planning influenza vaccination programs: a cost benefit modelDuncan Ian GTaitel Michael SZhang JunjieKirkham Heather S<p>Abstract</p> <p>Background</p> <p>Although annual influenza vaccination could decrease the significant economic and humanistic burden of influenza in the United States, immunization rates are below recommended levels, and concerns remain whether immunization programs can be cost beneficial. The research objective was to compare cost benefit of various immunization strategies from employer, employee, and societal perspectives.</p> <p>Methods</p> <p>An actuarial model was developed based on the published literature to estimate the costs and benefits of influenza immunization programs. Useful features of the model included customization by population age and risk-level, potential pandemic risk, and projection year. Various immunization strategies were modelled for an average U.S. population of 15,000 persons vaccinated in pharmacies or doctor’s office during the 2011/12 season. The primary outcome measure reported net cost savings per vaccinated (PV) from the perspective of various stakeholders.</p> <p>Results</p> <p>Given a typical U.S. population, an influenza immunization program will be cost beneficial for employers when more than 37% of individuals receive vaccine in non-traditional settings such as pharmacies. The baseline scenario, where 50% of persons would be vaccinated in non-traditional settings, estimated net savings of $6 PV. Programs that limited to pharmacy setting ($31 PV) or targeted persons with high-risk comorbidities ($83 PV) or seniors ($107 PV) were found to increase cost benefit. Sensitivity analysis confirmed the scenario-based findings.</p> <p>Conclusions</p> <p>Both universal and targeted vaccination programs can be cost beneficial. Proper planning with cost models can help employers and policy makers develop strategies to improve the impact of immunization programs.</p>http://www.resource-allocation.com/content/10/1/10InfluenzaImmunizationVaccinationCost benefitEconomic model
spellingShingle Duncan Ian G
Taitel Michael S
Zhang Junjie
Kirkham Heather S
Planning influenza vaccination programs: a cost benefit model
Cost Effectiveness and Resource Allocation
Influenza
Immunization
Vaccination
Cost benefit
Economic model
title Planning influenza vaccination programs: a cost benefit model
title_full Planning influenza vaccination programs: a cost benefit model
title_fullStr Planning influenza vaccination programs: a cost benefit model
title_full_unstemmed Planning influenza vaccination programs: a cost benefit model
title_short Planning influenza vaccination programs: a cost benefit model
title_sort planning influenza vaccination programs a cost benefit model
topic Influenza
Immunization
Vaccination
Cost benefit
Economic model
url http://www.resource-allocation.com/content/10/1/10
work_keys_str_mv AT duncaniang planninginfluenzavaccinationprogramsacostbenefitmodel
AT taitelmichaels planninginfluenzavaccinationprogramsacostbenefitmodel
AT zhangjunjie planninginfluenzavaccinationprogramsacostbenefitmodel
AT kirkhamheathers planninginfluenzavaccinationprogramsacostbenefitmodel